.jpg)
.png)
Top Stories
The Journal of Clinical Lipidology announced on Monday its 2016 Impact Factor has risen to 5.812, up from 4.906 in 2015. Led by Editor-In-Chief W. Virgil Brown, M.D., the JCL has seen a steady growth in submissions and readership since first publishing in 2007. It now ranks 17th of 256 journals in... more
On February 28, 2012, the Food and Drug Administration (FDA) approved crucial changes to the safety label for statins. The changes are based upon the FDA's further review of the data and are as follows: Removing the recommendation for periodic monitoring of liver enzymes; Adding a warning... more
Expert Panel Re-affirms the Importance of Setting Cholesterol Goals for the Prevention of Heart Attack and Stroke NEW YORK (Sept. 15, 2014) — Today, the National Lipid Association (NLA) released new recommendations based on a panel of independent experts, published in the Journal of... more
The National Lipid Association (NLA) was surveyed this year by the Accreditation Council for Continuing Medical Education (ACCME) and awarded Accreditation with Commendation for the next six years as a provider of continuing medical education for physicians. The NLA’s new accreditation term expires... more
Two new PCSK9 monoclonal antibodies have been given a nod of approval to the Food and Drug Administration (FDA). The FDA Endocrinologic and Metabolic Drugs Advisory Committee reviewed the evidence on the new class of cholesterol-lowering drugs and recommended that the FDA should approve the new... more
On January 29, the U.S. FDA approved mipomersen sodium injection as an adjunct to treat LDL-C, Apo B, total cholesterol, and non HDL-C in patients with homozygous familial hypercholesterolemia (HoFH). Mipomersen, known by the brand name Kynamro, will be marketed in the U.S. by Genzyme, a Sanofi... more
The National Lipid Association's (NLA) Annual Summary of Clinical Lipidology 2016 was just published the Journal of Clinical Lipidology. This year's summary enhances the NLA's established commitment to a patient-centered approach and individualized care, which is an approach now... more
On April 23, Amarin Corp. issued a press release announcing that the U.S. FDA has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high... more
The new ICD-10 Codes were released by the Center for Medicare & Medicaid Services (CMS). Two new specific codes for FH have been approved: E78.01: Familial hypercholesterolemia Z83.42: Family history of familial hypercholesterolemia The National Lipid Association (NLA) in... more
Patient-centered recommendations for people needing additional cholesterol reduction Download the NLA PCSK9 Update Infographic PHILADELPHIA — The National Lipid Association (NLA) assembled a panel of experts to update its guidance for the use of PCSK9 antibody therapy made in the... more